You are here: Industry Insights > Mankind

News List

Mankind Pharma gets DRDO nod to make and market 2-DG expresspharma
July 09, 2021
The company will manufacture the product at its facilities in Visakhapatnam and Himachal Pradesh.
Mankind partners with ace turtle for omnichannel transformation expresspharma
July 07, 2021
Mankind Pharma has partnered with ace turtle, an omnichannel platform company to accelerate its omnichannel transformation in India.
Mankind Pharma partners with BDR Pharma to distribute Baricitinib in India expresspharma
June 25, 2021
BDR Pharma will be manufacturing and marketing the product under a royalty-free, limited and non-exclusive voluntary licence from Eli Lilly and Company, and Mankind Pharma will be distributing the same.
Mankind Pharma launches Justoza, a Dapagliflozin approved by USFDA expresspharma
June 23, 2021
The Active Pharmaceutical Ingredient (API) is procured from the Drug Master File (DMF) facility approved by USFDA, EU GMP and WHO GMP, which ensures the highest global efficacy and safety standards.
Mankind Pharma launches Posaconazole tablets to treat black fungus expresspharma
June 11, 2021
Mankind Pharma has launched Posaconazole Gastro-Resistant tablets with the brand name POSAFORCE 100. Posaconazole gastro-resistant tablets are indicated for treating mucormycosis patients.
Mankind Pharma and Anil Kapoor partner to contribute Rs 1 crore to Maharashtra CM Relief Fund expresspharma
May 11, 2021
Also distributed Health OK multivitamin packets to Mumbai Police and covered the Juhu, DN Nagar, Versova, Khar, Bandra and ACP offices.
Mankind Pharma collaborates with Accenture for digital transformation with data-driven cloud platform expresspharma
May 08, 2021
Redesigns business processes and develops and deploys a digital platform to improve operational performance across its global presence.
Mankind Pharma seeks CDSCO approval for Phase 1 Clinical Trials of patented anti-diabetic molecule expresspharma
April 16, 2021
Mankind Pharma has submitted its first Investigational New Drug (IND) application for approval to Central Drugs Standard Control Organisation (CDSCO) for MKP10241, a patented novel anti-diabetic molecule.
Chrys Capital to buy 10% in Mankind for $350 M biospectrumasia
April 03, 2018
The deal may involve a secondary sale of shares by the promoter family, who currently hold 89 per cent stake in the company
Mankind forays into diagnostics with Pathkind expressbpd
March 30, 2017
Mankind Pharma is foraying into the diagnostics space with its new venture Pathkind Diagnostics.